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doi:10.1Objective: Pulmonary dysfunction/multiorgan failure syndrome is an important cause of mortality and morbid-
ity after cardiac operations. In this series, results of immune augmentation were assessed in patients experiencing
pulmonary dysfunction/multiorgan failure syndrome after cardiac surgery.
Methods: Since 2002, 44 consecutive patients with primary antibiotic-refractory pulmonary dysfunction/multi-
organ failure syndrome were treated with intravenous immunoglobulin (0.3 g/kg3 5 days; 1.5 g/kg total dose).
Thirty patients had undergone complex valve or aortic surgery, and 14 patients had coronary bypass. Median age
was 66 years, and risk profiles were especially high preoperatively. Clinical variables were assessed for 3 days
prior (3) to beginning intravenous immunoglobulin (on day 0) and for 5 days afterward (þ5). A postoperative
morbidity index was generated as aweighted sum of all relevant clinical variables. By using each patient as his or
her own control, the therapeutic effect of intravenous immunoglobulin was assessed with linear regression of
postoperative morbidity index over time with a spline and a knot at day 0, coincident with beginning intravenous
immunoglobulin.
Results:At day 0, all patients were deteriorating clinically and refractory to major antibiotics. Overall morbidity
was high, and immunoglobulin-G levels, obtained in the last 14 patients, were consistently low. By using linear
regression of postoperative morbidity index over time, intravenous immunoglobulin administration was associ-
ated with significant improvement in clinical status (P<.0001). A total of 42 of 44 patients (95%) recovered
uneventfully to hospital discharge. No significant complications of intravenous immunoglobulin therapy
occurred.
Conclusions: This experience suggests that management of immune dysfunction with intravenous immuno-
globulin is safe and effective for treatment of primary pulmonary dysfunction/multiorgan failure syndrome after
cardiac surgery. Expanded application seems indicated. (J Thorac Cardiovasc Surg 2011;142:575-80)A
C
D‘‘Still today, most of our postoperative problems can
be related to the deleterious effects of cardiopulmonary
bypass.’’
—John W. Kirklin, MD, Ward rounds, University of
Alabama Hospital, July 1970
Many postoperative complications after cardiac surgery
are associated with some degree of immune dysregula-
tion.1 Although exact mechanisms remain to be defined,
gram-negative pneumonia with opportunistic organisms
seem to require immune compromise, and problems
such as renal failure and thrombocytopenia often may
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The Journal of Thoracic and Cacardiac surgical patients may be predisposed to such prob-
lems, with a high incidence of critically ill compromised
patients preoperatively, the additional immune depleting
effects of cardiopulmonary bypass,2 and varying degrees
of malnutrition early postoperatively. At present, prob-
lems related to pulmonary infection/dysfunction and mul-
tiorgan failure syndrome (PD/MFS) are increasing,3,4
especially in patients undergoing valve surgery,5 who re-
quire longer cardiopulmonary bypass runs. In 2002, after
several deaths from postoperative pan-resistant gram-
negative pneumonia, it seemed reasonable to explore
other therapeutic options. Then, as now, no new gram-
negative antibiotics were close to development,6-11 and
after careful analysis of recent literature, it was elected
to augment and attempt to ‘‘normalize’’ function of the
immune system.1 The concept was to synergistically as-
sist antibiotic control of infection and to modulate inap-
propriate immune activation. At the time, intravenous
immune globulin (IVIG) was increasingly being used to
restore immune function toward ‘‘normal’’ in multiple
disorders, and application to patients postcardiac surgery
seemed logical. In this report, the results of a clinical ef-
fort of immune augmentation/modulation using IVIG for
primary PD/MFS after adult cardiac surgery are
described.rdiovascular Surgery c Volume 142, Number 3 575
Abbreviations and Acronyms
IgG ¼ immunoglobulin G
IVIG ¼ intravenous immune globulin
IVIgG ¼ intravenous immunoglobulin G
PD/
MFS
¼ pulmonary infection/dysfunction and
multiorgan failure syndrome
PMI ¼ postoperative morbidity index





The 44 patients described in this article represent a consecutive series
of patients in whom isolated antibiotic-refractory PD/MFS developed af-
ter cardiac surgery by the first author from 2002 to 2010. Criteria for di-
agnosis included pulmonary infiltrates associated with pulmonary
dysfunction and some degree of multiorgan failure, refractory to at least
24 hours of major antibiotic therapy. Outcomes of the first 15 patients
have been published,1 and the procedures and individual patient character-
istics of the whole series are listed in Table 1. Thirty patients had under-
gone complex cardiac valve or aortic surgery, and 14 patients had
coronary bypass. Median age was 66 years. Preoperatively, 98% of the
patients had significant comorbidity, 66% presented acutely, 45% were
hypoalbuminemic, and 32% had antecedent acute pulmonary derange-
ment. Preoperative total serum globulin levels were normal in all patients.
Preoperative IgG levels were low in some but were not obtained routinely.
Fourteen of the 44 patients experienced significant postoperative bleeding,
treated by blood component therapy, and 1 patient had required reopera-
tion for bleeding.
General Management Protocol
Postoperatively, patients had combinations of worsening pulmonary in-
filtrates; persistent signs of sepsis (eg, high cardiac output, low systemic
vascular resistance, chills, rigors, fever, and delirium); leukocytosis;
deterioration of pulmonary mechanics; and impairment of pulmonary gas
exchange, despite receiving at least 24 hours of major triple-drug intrave-
nous antibiotics (consisting of combinations of piperacillin/tazobactam,
cefepime, tobramycin, and meropenem; vancomycin was used only for
specific indications). In general, the University of Kentucky antibiotic ap-
proach for management of hospital-acquired pneumonia was used,12 and
having an effective antibiotic protocol seemed to be important.
In this series of patients, no other complications or sources of infection
were present, such as gastrointestinal sepsis and so forth. All patients were
moved back to an intensive care unit setting and had documentation of
good cardiac status with a Swan-Ganz catheter and a transthoracic echo-
cardiogram at the outset to rule out cardiac cause of pulmonary infiltrates
and PD/MFS. Pulmonary cultures were obtained in all patients, including
bronchial washings or protected brush cultures in patients undergoing
therapeutic fiberoptic bronchoscopy. Renal failure was also developing
in 28 of the 44 patients (64%), manifested by oliguria or anuria with in-
creasing creatinine, despite intravenous dopamine and diuretic support.
Important general clinical management principles also were emphasized,
such as early enteral nutrition, avoidance of total parenteral nutrition,
minimization of central lines as sources of infection, aggressive pulmo-
nary care, ongoing optimization of cardiopulmonary function, effective
arrhythmia management,13 and standard postoperative care. If it seemed
that prolonged supplemental enteral nutrition would be needed, a percuta-
neous endoscopic gastrostomy tube was placed. In cases associated with
profound thrombocytopenia, anticoagulation with thrombin inhibitors
and platelet transfusions were avoided, and the patients were treated
with IVIG only.576 The Journal of Thoracic and Cardiovascular SurgIntravenous Immune Globulin Therapy
When the patient was documented as deteriorating despite conventional
therapy, the family was engaged in a discussion of the situation and ex-
plained the potential advantages and complications of immune boost
with IVIG. At the time, literature support existed for this form of immune
intervention.14-22 All families agreed, and then high-dose IVIG therapy
(Carimune, ZLB Behring Inc, King of Prussia, Pa) was begun at a dose
of 18 or 24 g per day (depending on the size of the patient; 0.3 g/kg) in-
travenously for 5 days to a total dose of 1.5 g/kg. In the subsequent analysis,
the first day of IVIG infusion was considered IVIG day 0.
Analysis Protocol
Perioperative clinical variables were combined into one number, the
postoperative morbidity index (PMI), to quantify overall time varying
changes in clinical status. Clinical variables were worsening pulmonary
infiltrates (I) on the chest radiograph; leukocytosis (L); pulmonary
dysfunction (P); ventilator requirement (V); septic shock (S); renal (R),
gastrointestinal (G), and hepatic (H) dysfunction; thrombocytopenia (T);
and delirium (D). Variables were documented by retrospective chart review
for 3 days prior (day3) to beginning IVIG therapy (on day 0) and for 5
days afterward (dayþ5). PMI was used to quantify the clinical condition
in a given patient, on a given day, with one number. The ‘‘weighting’’ of
each variable was determined before the analysis began, based on esti-
mated subjective clinical importance. PMI was calculated as the sum of
I: 1 ¼ minor infiltrate in one lobe, 3 ¼ moderate infiltrates in more than
1 lobe, 5 ¼ severe infiltrates throughout both lungs, 7 ¼ complete pulmo-
nary ‘‘white-out’’; L: 1 for each 2K increase in white blood count above
10K; Pwas divided into sputum: 1¼ severe cough only, 2¼ purulent spu-
tum, 3 ¼ positive sputum culture; increasedwork of breathing: 1¼mild,
2 ¼ moderate, 3 ¼ severe; and oxygen requirement: 1 ¼ mild (O2 re-
quirement¼40%), 2 ¼ moderate (50%–70% O2), 3 ¼ severe (100%
O2); V: 5 for requirement of mechanical ventilation; S: 3 for mean arterial
pressure less than 65 mm Hg with cardiac index greater than 3.0 on intra-
venous catecholamines; R: 1 for each 0.4 mg/dL increase in creatinine
greater than 1.5 mg/dL; G: 2 for ‘‘ileus’’ diagnosed on abdominal radio-
graph; H: 2 for any elevation in bilirubin or hepatic enzymes documented;
T: 2 for platelet count less than 60K; and D: 2 for delirium requiring
pharmacologic therapy. By using each patient as his or her own control,
the therapeutic effect of intravenous immunoglobulin G (IVIgG) was
assessed with linear regression analysis of PMI over time with a spline
and a knot at day 0, coincident with beginning IVIgG.
This trial of IVIG for the purpose of treating PD/MFSwas initiatedwithin
a clinical cardiac surgical practice in the setting of a worsening high-risk
problem with limited available solutions. An off-label application of an
Food and Drug Administration-approved drug was used, and the concept
was based on existing literature support at the time.14-26 The chart review
and analysis was performed at a later date under a waiver of informed
consent by the Western Institutional Review Board for assessment of an
individual surgeon’s outcomes with deidentified patient variables.RESULTS
At the time of initiation of IVIG therapy, every patient was
worsening rapidly, with impending need for reintubation or
ventilatory requirement in most, despite broad-spectrum
intravenous antibiotics for at least 24 hours previously. No
patient in this series had other complications or evidence
of alternative sources of infection. In the linear regression
analysis of PMI over the 3 days before IVIG, the patients’
clinical status was deteriorating significantly (slope ¼ 3.59,
standard error¼ 0.41, t¼ 8.62,P<.0001).When the decision
for IVIgG was made (day 0), morbidity included I-100%,ery c September 2011
Rankin et al Acquired Cardiovascular Disease
A
C
DL-95%, P-95%, V-48%, S-25%, R-64%, G-20%, H-7%,
T-32%, and D-9%. IgG levels, obtained in the last 14 pa-
tients, were consistently low (Table 1). After beginning
IVIG at day 0, improvement in clinical course was observed
uniformly over the subsequent 5 days (slope ¼1.98, stan-
dard error¼ 0.20, t¼ 9.75, P<.0001). In the spline function
analysis and using eachpatient as his or her owncontrol, IVIG
administration was associated with significant improvement
in clinical status (P<.0001), as evidenced by a decrease in
PMI toward normal over the course of immune augmentation
(Figure 1). Despite serious baseline profiles at day 0, 42 of 44
patients (95%) recovered uneventfully to hospital discharge.
No significant complications of IVIgG therapy occurred.
In 1 patient exhibiting profound thrombocytopenia with
schistocytes and a negative heparin antibody test result, plas-
mapheresis was used over 3 days, in addition to concomitant
IVIG therapy, with a prompt clinical response. This patient
also received extra doses of immunoglobulin to compensate
for losses due to plasma exchange. Pulmonary cultures were
positive in less than one third of patients, usually with resis-
tant gram-negative organisms; however, Pneumococcuswas
present in 1 patient. One patient had an initial good response,
but progressive sepsis then developed and he died. He had
bled into his right lung early postoperatively, and it was dif-
ficult to clear the infection in his lung. The second patient in
the series who died had a hypoxic respiratory arrest after
removing his oxygen mask during an episode of delirium.
He was responding to IVIG nicely at the time, and more
careful observation might have prevented the death. Al-
though recovery of serum creatinine was prolonged in sev-
eral patients with acute renal failure, all surviving patients
recovered renal function to preoperative levels.
DISCUSSION
An in-depth discussion of immune function in this setting
and the mechanisms of IVIG action has been published.1
Briefly, IVIG contains active human antibodies from more
than 4000 patients in a region. Administration in patients
with PD/MFSmayprovide attack antibodies to augment con-
trol of any given infection, but perhapsmore important, mod-
ulatory antibodies regulate the immune response, resolving
inappropriate immune activation and inflammation.Whether
considering inflammatory mediators, activated complement,
inappropriate autoantibodies, or bacterial superantigens,
IVIG in these doses functions to return the immune system
toward normal after the dysregulating effects of surgery
and cardiopulmonary bypass.1 Although IVIG is a human
blood product, sterilization using a nanofiltration system
has been effective, with no disease transmission documented
in millions of doses.20,21 At the doses used in this article,
renal injury associated with globulin administration has
been rare and was nonexistent in this series.
Much of the organ toxicity associated with pulmonary
infection is mediated by microbial products calledThe Journal of Thoracic and Ca‘‘superantigens’’23,24 that cause direct cellular injury and
activate T lymphocytes to release abundant cytokines.
Neutralizing antibodies to superantigens exert strong
antitoxin effects, with immunomodulatory consequences.
Scavenging of superantigens is a major action of IVIG for
treatment of multiorgan failure associated with systemic
infection, and IVIG seemed effective in reversing organ
dysfunction in the present series. In fact, we have never
before had a clinical approach that could directly treat, and
almost immediately reverse, postoperative renal failure.
Patients exhibiting thrombocytopenia probably also are
responding to one of several superantigens, or even
uncontrolled autoantibodies, which induce aggregation
and peripheral deposition of platelets, and further
contribute to organ failure by causing microcirculatory
underperfusion.26 IVIG therapy seemed effective in revers-
ing thrombocytopenia, and the addition of plasmapheresis in
an extreme casewas adjunctive. It has been efficacious to ap-
ply IVIG (and adjunctive plasmapheresis when necessary)
to cases of early postoperative profound thrombocytopenia,
potentially caused by PF4 heparin antibodies (heparin-in-
duced thrombocytopenia), thrombotic thrombocytopenic
purpura-like antibodies, or infectious causes.27,28 In fact,
most postoperative microangiopathies may be just further
examples of ‘‘immune dysregulation syndrome.’’
In the present study, patients who developed PD/MFS
often were elderly, had significant comorbidity, and were
hospitalized with acute illness, exhibiting nutritional and
potentially immunologic depletion on admission. Hypoal-
buminemia was an important marker and may reflect nutri-
tionally based inability to synthesize protein, and thus
immunoglobulins. Acquired immune defects may even
be required for gram-negative pneumonia to occur. Patients
frequently displayed preoperative pulmonary injury or in-
fection and were primarily complex valve cases. One
might speculate that longer cardiopulmonary bypass and
endotracheal intubation times could be important in the
pathogenesis. A history of postoperative bleeding (a
known risk factor for infection) was common in this pop-
ulation, and when treated with blood component therapy
devoid of globulins may have led to worse depletion of
immunoglobulins.
Several limitations of this study need to be documented.
First, the PMI was developed prospectively to quantify clin-
ical status with one number. The exact scores, however,
were selected arbitrarily, based (one might say) on ‘‘expert
opinion.’’ A more objective score assignment might be use-
ful in the future, using, for example, coefficients generated
by logistic regression analysis. Several of the variables,
such as radiographic degree of lung infiltrates, also were
subjective. Thus, the PMI has to be considered a semiquan-
titative tool, although directional clinical changes and the
high degree of ultimate recovery would be independent of
exact scores assigned. This study is a retrospective analysisrdiovascular Surgery c Volume 142, Number 3 577
TABLE 1. Patient characteristics





1 56 M 1 No IE I IV
2 77 M 4 No CAD I III
3 62 M 4 No Ischemic mitral disease IV I
4 41 F 2 No Rheumatic disease I IV
5 75 M 1 No CAD IV I
6 69 M 3 No CAD IV I
7 78 M 4 No Prolapse I IV
8 57 M 2 No CAD IV I
9 54 M – No Marfan syndrome or other connective tissue disease. I IV
10 69 M 2 No Prolapse I IV
11 77 M 3 No Calcified valve disease I IV
12 77 M 3 No Prolapse I IV
13 69 F 1 Yes Prolapse I III
14 78 F 4 No CAD IV I
15 67 F 4 Yes, 33 Ischemic mitral disease I IV
16 59 M 2 No CAD IV I
17 81 F 1 No Calcified valve disease I IV
18 67 M 1 No CAD I III
19 51 M 2 No CAD IV I
20 60 M 3 Yes CAD IV I
21 75 M 3 No CAD III I
22 75 M 3 No CAD I III
23 57 F 1 No Rheumatic disease I III
24 53 M 1 No CAD IV I
25 67 M 4 No PAD I III
26 44 M 3 No CAD IV I
27 60 M 3 No Marfan syndrome or other connective tissue disease I IV
28 79 M 3 No Ischemic mitral disease I IV
29 70 M 1 No CAD IV I
30 59 F 1 No Calcified valve disease I III
31 49 M 2 Yes, 53 Marfan syndrome or other connective tissue disease I I
32 69 M 1 No Calcified valve disease I III
33 67 F 2 No PAD I IV
34 77 M 2 No Calcified valve disease I IV
35 57 F 2 No CAD IV I
36 77 F 1 No PAD I IV
37 77 M 3 No Prolapse I IV
38 80 F 2 No Calcified valve disease I IV
39 39 F 3 Yes Congenital heart disease I IV
40 57 M 3 No CAD I III
41 62 F 3 Yes HOC I III
42 59 M 2 Yes IE I IV
43 77 M 3 Yes PAD I IV
44 90 M 2 No Prolapse I IV
CM, Number of comorbidities; CAD, coronary artery disease; IE, infectious endocarditis; PAD, pure annular dilatation; HOC, hypertrophic obstructive cardiomyopathy; NYHA,
NewYork Heart Association; CHF, congestive heart failure; N, normal; PE, pulmonary edema; BS, balloon pump for shock; AP, acute presentation; C, coronary bypass; A, aortic
valve;M,mitral valve; T, tricuspid valve; VR, valve repair/replacement; VSD, patch closure of ventricular septal defect; Bentall, aortic root replacement; Smy, septal myectomy;
AAA, ascending aortic aneurysm; Tr, transfusion of  4 units of packed red cells,  4 units of fresh-frozen plasma, and  6 units of platelets (patient 13 required reoperation for
bleeding); IgG, postoperative immunoglobulin G levels. Normal albumin for this laboratory is>3.4, and normal IgG is>680.
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Dof a clinical experience, and undefined or confounding vari-
ables may have influenced results. However, with such
a consistent response in 44 consecutive patients, and with
the strong results of the spline analysis using each patient
as his or her own control, the presence of a significant578 The Journal of Thoracic and Cardiovascular Surgtreatment effect is highly probable. In the authors’ opinion,
a randomized trial now would be unethical, although future
studies of mechanisms seem indicated. Finally, IgG levels
were only available in the latter part of the series, but it






presentation Procedure Pump time Transfusion
Postoperative
IgG levels
PE 2.9 Y AMT-VR, VSD 3:06 No –
N 2.8 N C34 1:36 No –
N 3.4 Y AM-VR, C34 4:05 No –
N 3.8 Y MVR 2:06 No –
N 2.7 Y C32 1:05 Yes –
N 3.6 Y C34 2:19 No –
N 3.4 Y MVR, C32 2:56 No –
N 2.7 Y C35 2:22 No –
N 3.0 Y Bentall 3:19 Yes –
PE 2.0 Y MT-VR 3:21 Yes –
N 3.3 N A-VR, C34 2:40 Yes –
PE 2.2 Y MVR, C31 3:01 No –
N 3.8 N MVR, radiofrequency ablation 1:54 Yes –
BS 2.7 Y C34 1:26 Yes –
N 3.6 Y MT-VR 3:40 Yes –
N 3.1 Y C34 2:30 No –
N 2.8 Y A-VR, C31 1:58 No –
N 2.9 N MVR, C33 3:30 No –
N 3.0 Y C34 1:52 No –
N 3.9 N C33 3:48 Yes –
N 4.0 Y C34 2:01 Yes –
N 3.9 N C34 1:40 No –
N 3.8 N MVR 3:02 No –
N 3.5 Y C33 1:33 No –
N 3.9 Y MT-VR, radiofrequency ablation 2:01 No –
N 4.2 Y C31 1:25 Yes –
N 2.9 Y AVR, AAA 2:12 No –
PE 3.2 Y MVR, C34 2:46 No –
N 3.7 Y C35 1:43 No –
N 3.5 N AVR, C34 1:50 No 315 –
N 3.4 N TAA 6:30 Yes 481
N 3.5 N AVR, C31, SMy 2:38 No 269 359
N 3.4 N MT-VR, C31 4:06 No 498 525
N 3.2 Y AM-VR, C32, AAA, radiofrequency ablation 4:33 No 368
N 3.7 Y C32 1:33 No 255
PE 3.0 Y AMT-VR, radiofrequency ablation 3:35 Yes 487
N 3.4 Y AM-VR, radiofrequency ablation 4:08 Yes 546
N 3.7 N AVR, root enlargement 3:20 No 537
N 4.1 N MVR, radiofrequency ablation 4:26 No 704
N 3.7 N C33, radiofrequency ablation 3:26 No 358
N 2.9 N MVR, C31, SMy 3:01 Yes 587
N 3.5 Y MVR 3:06 No 788
N 3.0 Y AMT-VR, radiofrequency ablation 4:20 No 105
PE 2.9 Y MVR, radiofrequency ablation 2:52 No 467 386
TABLE 1. Continued
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DFuture analysis of postoperative immunoglobulin levels
relative to outcomes could be illuminating.
In current practice, postoperative PD/MFS is the most
important cause of morbidity and mortality.29 Moreover,
the incidence may be increasing with the emergence ofThe Journal of Thoracic and Camultidrug-resistant bacteria. Strategies to control the
problem include better antibiotic stewardship, and impor-
tant antibiotic protocols have been developed that can
reverse antibiotic resistance patterns. Potential sources of
nosocomial infection also should be addressed,30 and it isrdiovascular Surgery c Volume 142, Number 3 579
FIGURE 1. Mean standard deviation of course of PMI for 3 days before
(3) to 5 days after (þ5) beginning IVIgG therapy in 44 postoperative
patients. IVIgG therapy was begun on day zero (0). IVIgG was associated
with a consistent reversal of worsening of postoperative morbidity and
a highly significant treatment effect, using each patient as his/her own
control (P< .0001). See text for details. PMI, Postoperative morbidity
index; SD, standard deviation; IVIG, intravenous immunoglobulin.
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Dpossible that operating room anesthesia ventilators have
been significant culprits, providing a reservoir in many hos-
pitals for resistant gram-negative pulmonary infections.
Better infection control may be the ultimate approach to
this problem, although it is unlikely that postoperative
pneumonia after cardiac surgery could be completely elim-
inated. Finally, correlating our results with the findings of
the ESSICS trial31 is difficult. In the 2 series, patient selec-
tion probably was different, the IVIG may not have been as
active as currently used preparations, and, most important,
doses used in the ESSICS trial were clearly subtherapeu-
tic.32 Thus, the conclusion of that trial that IVIG was inef-
fective in postoperative cardiac surgery patients could have
been an artifact of study design.CONCLUSIONS
IVIG administered to patients experiencing antibiotic-
resistant PD/MFS after cardiac surgery promptly and effec-
tively reversed clinical deterioration and seemed efficacious
and safe. Immune dysregulation may play an important role
in PD/MFS, and immune augmentation with IVIG offers
the exciting possibility of effectively treating one of themajor
problemsencountered incardiac surgical practice today.Stud-
ies of immunomodulatory mechanisms also seem indicated.References
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